JZL184


Selective MAGL inhibitor (research)

A covalent inhibitor of monoacylglycerol lipase (MAGL); the canonical research probe for elevating endogenous 2-AG.

Abstract

JZL184 (CAS 1101854-58-3; molecular formula C27H24F2N2O5; molecular weight 510.49) is a covalent piperidinyl-carbamate inhibitor of monoacylglycerol lipase (MAGL) developed by Cravatt and colleagues at Scripps. The compound carbamoylates the active-site serine of MAGL, producing irreversible enzyme inactivation. Selective for MAGL over FAAH (approximately 300-fold) and other serine hydrolases. Pharmacological consequence: elevation of endogenous 2-AG (the principal full-agonist endocannabinoid) without direct CB receptor agonism. Behavioral effects are more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at high dose), reflecting the higher tonic CB1 occupancy from elevated 2-AG. Used as the canonical MAGL inhibitor in academic neuroscience for studies of 2-AG signaling and CB1-mediated synaptic plasticity. No human clinical development.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph